Targeting Podoplanin for the Treatment of Osteosarcoma.

ABSTRACT:

Purpose

Osteosarcoma, the most common bone malignancy in children, has a poor prognosis, especially when the tumor metastasizes to the lungs. Therefore, novel therapeutic strategies targeting both proliferation and metastasis of osteosarcoma are required. Podoplanin (PDPN) is expressed by various tumors and is associated with tumor-induced platelet activation via its interaction with C-type lectin-like receptor 2 (CLEC-2) on platelets. We previously found that PDPN contributed to osteosarcoma growth and metastasis through platelet activation; thus, in this study, we developed an anti-PDPN humanized antibody and evaluated its effect on osteosarcoma growth and metastasis.

Experimental design

Nine osteosarcoma cell lines and two osteosarcoma patient-derived cells were collected

SUBMITTER: Takemoto A 

PROVIDER: S-EPMC9359727 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature